What a conversation with Pacira’s medical science liaisons revealed about liposomal bupivacaine, geriatric patients, and the still-fuzzy question of total local anesthetic load. Some perioperative questions seem like they should have a clean answer. Then you start pulling on the thread.
That is where I found myself after a recent discussion with medical science liaisons from Pacira about EXPAREL – liposomal bupivacaine – and a question that, in my opinion, deserves far more attention than it usually gets.
How should clinicians think about total local anesthetic burden when EXPAREL is combined with additional bupivacaine, especially in older adults?
This was not an academic exercise. It came from a very real-world problem: a breakdown in communication between the surgical team and the anesthesia team that resulted in a patient receiving a larger-than-expected cumulative local anesthetic exposure. That kind of event immediately forces a more uncomfortable question:
Who is actually keeping track of the total dose?
And once you ask that question honestly, you realize the issue is bigger than one drug, one block, or one case.
“Delayed release does not equal dose irrelevance.”
The problem did not start with pharmacology. It started with workflow.
This whole issue began the way many perioperative safety problems begin: not with a bad intention, but with a fragmented plan.
One clinician is thinking about the block.
Another is thinking about surgeon infiltration.
Someone else is thinking about postoperative pain control.
Everyone assumes the cumulative dose is reasonable.
Not everyone is working from the same mental model.
In a large academic center, a lot of these problems are buffered by layers of expertise, subspecialty familiarity, pharmacy support, and institutional redundancy.
In a critical access hospital, those buffers may not exist. That means the margin for error is narrower, and the need for a simple, defensible framework becomes much more important. When you are practicing in an environment where you may be the only person in the room fully focused on the systemic toxicity implications of cumulative local anesthetic dosing, “we usually do this” is not a sufficient answer.
Our classic local anesthetic framework no longer fits as neatly.
For most anesthesia clinicians, the traditional framework for local anesthetic dosing is straightforward. You think about:
- the drug
- the total milligrams
- whether epinephrine is present
- the patient’s weight
- the vascularity of the site
- the speed of absorption
- and the patient factors that make toxicity more or less likely
That framework works reasonably well for plain local anesthetics. Then EXPAREL enters the conversation, and suddenly the math gets strange. Now the question is no longer just:
How much bupivacaine are we giving?
It becomes:
How much of this matters immediately, how much is delayed, and how should that affect the way we think about LAST risk?
That is where bedside certainty starts to erode.
“Reassuring pharmacokinetic curves are helpful. They are not the same thing as a bedside dosing framework.”
What Pacira’s team made clear.
To their credit, the medical science liaison team was careful and appropriately measured in how they answered.
Their explanation centered on a few important points:
- EXPAREL contains a small unencapsulated fraction that is available relatively early.
- The remainder of the bupivacaine is released gradually as the liposomal structure breaks down over time.
- Their safety discussion relies heavily on pharmacokinetic data, particularly plasma concentration curves.
- In the available data they referenced, mean plasma concentrations generally remained below commonly cited toxicity thresholds.
- They do not appear to have a simple, universally applicable manufacturer-driven formula for calculating a combined “total anesthetic load” in the same way anesthesia clinicians often think about plain local anesthetic dosing.
That last point is the most important one. Because while PK data can be reassuring, clinicians at the bedside still need to make practical choices in actual patients, not average curves. And that brings us to the real friction point.
The real missing piece: age and weight.
The core of my questioning was not whether EXPAREL is pharmacologically interesting. It clearly is. The core issue was this:
When the patient is older, smaller, frailer, or physiologically less forgiving, how should that influence the way we interpret total local anesthetic exposure when EXPAREL is part of the plan?
That is how anesthesia clinicians think. We do not look at a 78-year-old the same way we look at a 42-year-old. We do not look at a 60-kilogram patient the same way we look at a 100-kilogram patient. We do not ignore changes in:
- body composition
- total body water
- volume of distribution
- protein binding
- reserve
- recovery capacity
So when the main reassurance offered is that plasma concentrations in study populations stayed below certain thresholds, the next logical question is:
Which patients?
Were those older but robust patients? Were they low-BMI or higher-BMI? Were they in their early 60s, or did the data meaningfully include 75- to 80-year-olds in a way that helps inform bedside practice?That is where the answers became less precise.
Some studies did include older adults. Some cohorts reached into the 80s. But the kind of granular patient-level breakdown that would help a clinician say, “Yes, this supports my plan in this particular elderly patient,” did not seem readily available. That matters. Because for many of us, especially those practicing outside large tertiary centers, that is exactly the level of confidence we are looking for.
What I found encouraging—and what I did not.
I found the candor of the discussion encouraging. The MSL team did not try to manufacture certainty where certainty was lacking. They acknowledged that they do receive questions about total anesthetic load. They acknowledged that their answer is generally built around pharmacokinetic materials and the mechanistic explanation of delayed release. And they acknowledged that they do not currently have robust data that produce a precise, age- and weight-adjusted adult dosing framework for combined local anesthetic load. That honesty is useful. What is less satisfying, of course, is what it means in practice.
Because it means many clinicians are left doing what clinicians often do when evidence is incomplete: combining the best available pharmacology, the available safety literature, personal experience, and conservative judgment. That is not wrong. But it is not the same as having a validated rule.
“The absence of frequent disaster is not the same thing as the presence of a validated dosing framework.”
The practical temptation: if nobody is getting hurt, maybe the concern is overstated. This is the trap.
A surgeon says, “We do this all the time.”
A colleague says, “Nobody’s had a problem.”
A facility down the road does even more.
The plasma curves look reassuring.
The package insert does not hand you an alarm bell.
So maybe the concern is overblown? Maybe. But that is not the same as saying the issue has been answered. There is a difference between:
- common practice
- plausible pharmacology
- and explicit evidence-based bedside guidance
Those are not interchangeable.
And in medicine, especially perioperative medicine, we get into trouble when we start treating them as though they are.
What I think is probably true.
After hearing the discussion and thinking through the logic, I think a few practical conclusions are fair.
First, EXPAREL should not be thought of as if its entire bupivacaine content behaves like an immediate bolus of plain bupivacaine. The release kinetics matter. That is the entire point of the formulation. Second, the early toxicity window is likely influenced much more by the immediately available free fraction and any additional plain bupivacaine than by the total encapsulated amount that will release over time. Third, that does not make the liposomal dose irrelevant. It just means the timing of risk is different from the timing associated with plain bupivacaine alone. And fourth, elderly patients deserve more, not less, caution when the dosing picture gets complicated.
That last point remains true even if the graphs are reassuring.
Why this matters so much in smaller hospitals.
In a major academic system, uncertainty is often diluted across teams. In a critical access hospital, uncertainty becomes personal.
That is why this question matters so much to me.
If the anesthesia clinician, surgeon, circulator, PACU team, and leadership structure are all working from slightly different assumptions about whether EXPAREL “counts” toward the total local anesthetic burden, then the safety problem is not theoretical. It is operational.
And operational problems create clinical risk long before toxicity ever appears. That is the bigger lesson here. The issue is not just pharmacokinetics. It is whether institutions have built a process that prevents cumulative dosing confusion in the first place.
What hospitals should probably do right now.
Until stronger age-stratified and weight-sensitive data exist, the most defensible answer is not to pretend the ambiguity is gone.
It is to create better structure around the ambiguity.
That means:
- deciding who owns the local anesthetic plan for the case
- ensuring surgeon infiltration and anesthesia regional plans are discussed before injection
- accounting for all local anesthetic-containing agents in one shared conversation
- using extra caution in elderly, frail, or low-body-mass patients
- and resisting the tendency to let routine practice substitute for deliberate dose planning
In other words, better systems before bigger doses.
“The danger usually does not begin when the lipid rescue kit comes out. It begins earlier, when multiple people think someone else is keeping track of the dose.”
My bottom line.
After this conversation, my position is more refined, but not less cautious.
I do not come away thinking EXPAREL is reckless. I do not come away thinking the available data are alarming. I do come away thinking that the bedside framework many clinicians want—particularly for elderly adults—still feels incomplete.
So for now, my own practical stance is this:
Respect the pharmacokinetics. Do not treat liposomal bupivacaine as identical to plain bupivacaine. Do not ignore it either. Stay especially conservative in older adults. Above all, build communication systems that prevent cumulative local anesthetic dosing errors before they happen.
Because in perioperative medicine, the most dangerous phrase is often not:
“This is unsafe.”It is: “Everyone does it.”